A 45-year-old woman underwent a modified radical mastectomy 4 years ago. She was treated for multiple bone metastases with cyclophosphamide, doxorubicin, and fluorouracil for 6 months. She is complaining of exertion on exercise, swelling of the legs, and swelling around eyes in the morning. On examination, she has bilateral rales in the lungs, S1, S2 audible, S3, S4 gallop present. Her BP is 149/117 mm Hg, PR is 80/min, and RR is 18/min. What is the most likely cause for her cardiac condition?

## **Core Concept**
The patient's symptoms and signs suggest heart failure, which can be caused by various factors including chemotherapy agents. The key here is to identify which chemotherapy agent is most likely to cause cardiotoxicity leading to heart failure.

## **Why the Correct Answer is Right**
The patient was treated with cyclophosphamide, doxorubicin, and fluorouracil. Among these, **doxorubicin** is well-known for its cardiotoxic effects. Doxorubicin works by intercalating DNA strands, thereby inhibiting the synthesis of macromolecules and inducing apoptosis in cancer cells. However, it also generates free radicals that can damage cardiac myocytes, leading to cardiomyopathy and heart failure. The symptoms presented, such as exertional dyspnea, swelling of the legs, periorbital edema, bilateral rales, and an S3 gallop, are indicative of heart failure. The presence of hypertension could also contribute to cardiac strain but is less directly linked to the acute presentation of heart failure in this context.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While cyclophosphamide can have cardiac effects, especially at high doses (e.g., in stem cell transplant regimens), it is less commonly associated with cardiotoxicity compared to doxorubicin in conventional chemotherapy doses.
- **Option B:** Fluorouracil can cause cardiotoxicity but is less commonly associated with the chronic cardiomyopathy and heart failure seen with doxorubicin.
- **Option D:** This option is not provided, but typically, other chemotherapeutic agents not listed could have various side effects, though they are less directly implicated in cardiotoxicity compared to doxorubicin.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **doxorubicin-induced cardiotoxicity** can be dose-dependent, and the risk increases significantly at cumulative doses above 450 mg/m^2. Monitoring cardiac function, such as with echocardiograms or MUGA scans, is recommended in patients receiving high cumulative doses.

## **Correct Answer:** . **Doxorubicin**

✓ Correct Answer: B. Drug induced cardiac toxicity